# Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS

> **NCT03238534** · PHASE4 · COMPLETED · sponsor: **Aboca Spa Societa' Agricola** · enrollment: 275 (actual)

## Conditions studied

- GERD
- EPS

## Interventions

- **DEVICE:** Neobianacid®
- **DRUG:** Omeprazole 20mg
- **OTHER:** Neobianacid® placebo
- **OTHER:** Omeprazole placebo

## Key facts

- **NCT ID:** NCT03238534
- **Lead sponsor:** Aboca Spa Societa' Agricola
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-12
- **Primary completion:** 2021-09-03
- **Final completion:** 2021-09-03
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2022-11-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238534, "Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03238534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*